Media headlines about Covance (NYSE:CVD) have trended somewhat positive on Wednesday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Covance earned a news impact score of 0.08 on Accern’s scale. Accern also gave media stories about the healthcare company an impact score of 46.491901823818 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
TRADEMARK VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/covance-cvd-receives-news-sentiment-rating-of-0-08/1701174.html.
Covance Company Profile
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with our FREE daily email newsletter.